FEB 16, 2018 7:00 AM PST

Clinical Trial for Cannabidiol Effect on Hyperphagia in Affected Individuals with Prader-Willi Syndrome

WRITTEN BY: Mauri Brueggeman

Photo Source: healthworxcbd.com

There is a Phase II randomized, double-blind clinical trial in the United States currently recruiting patients with Prader-Willi Syndrome (PWS) to evaluate the efficacy of cannabidiol (liquid form) use on hyperphagia (overeating) related behavior. Cannabidiol (CBD) is an agonist for receptors in the human Endocannabinoid System (ECS). INSYS Therapeutics Inc. is the sponsor of the trial which is set to start March 2018 and run through May 2018 according to the National Institutes of Health US Library of Medicine where clinical trials are documented.

Prader-Willi syndrome is a complex human genetic condition related to genomic imprinting on the acrocentric chromosome 15, specifically locus 15q11.2 region. This region is in the proximal arm of chromosome 15 right below the centromere. Imprinting is a complicated and not wholly understood genetic process whereby gene expression is regulated through epigenetic silencing (typically by methylation). The etiology of the disorder is the failure of expression of the gene located within 15q11.2 on the paternally inherited chromosome 15. The typical resulting phenotype begins in infancy with weak muscle tone, feeding difficulties, and developmental delay; successive appetite increases beginning in early childhood and by age 8 result in children with PWS having an insatiable appetite and an uncontrollable focus on food. Weight management and obesity are consistent challenges due to hyperphagia. Prader-Willi syndrome (PWS) results from three basic causes: (1) the deletion of the 15q12 region on the paternally inherited chromosome. This is likely and most often due to random events during the formation of sperm or early in fetal development; (2) the random inheritance of two copies of the mother’s chromosome 15’s, defined as an example of uniparental disomy. The medical terminology can be broken down into parts which results in: “Uni-“ = one/single, “parental” = parent, “di-” = two [copies], “somy” = [relating to] chromosomes; (3) Inheritance occurred normally but there was a defect in the imprinting process in the 15q11.2 chromosomal region.

Photo Source: University of Floria Department of Pediatrics

The human ECS plays a regulatory role in endocrine and metabolic functions, along with the central nervous system, for appetite control, food intake, and energy balance. A 2011 study in the journal of Pharmacology and Biochemical Behavior found that CBD can act as an agonist for CB1R by blocking the uptake of the human endocannabinoid molecule anandamide. There are multiple systems collaborating for food intake control including both the cannabinoid and serotinergic pathways. Williams and Kirkham (2002) published research focused on the role of SR141716A (rimonabant), a CB1R antagonist, which was shown to reverse the hyperphagic effect caused by the phytocannabinoid delta-9 tetrahydrocannabinol (THC). Rimonabant suppresses food intake signaling; CBD is an alternative cannabinoid that has similar antagonistic effects as rimonabant though may target different receptors than CB1R. CBD on its own may not change food intake but may prevent or disrupt the physiological process leading to hyperphagia.

Sources: Pharmacology, Biochemistry and Behavior (2011); Pharmacology, Biochemistry and Behavior(2002)National Institutes of Health International Conference on HyperphagiaNational Institutes of Health US Library of Medicine

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
JUL 13, 2020
Cannabis Sciences
Cannabis Briefly Alleviates PTSD Symptoms
JUL 13, 2020
Cannabis Briefly Alleviates PTSD Symptoms
Therapy is the primary recommended treatment for individuals with post-traumatic stress disorder (PTSD), but a new study ...
JUL 29, 2020
Cannabis Sciences
Stimulants, Cannabis, and Medical Cannabis Laws
JUL 29, 2020
Stimulants, Cannabis, and Medical Cannabis Laws
Lesbian, gay, and bisexual populations may be at a higher risk of prescription stimulant use, based on a new examination ...
AUG 14, 2020
Cannabis Sciences
CBD Increases Blood Flow to Brain's Memory Center
AUG 14, 2020
CBD Increases Blood Flow to Brain's Memory Center
Researchers from University College London in England have found that a single dose of cannabidiol (CBD) increases blood ...
SEP 05, 2020
Cannabis Sciences
Moderate Cannabis Use in Teenagers Reduces Cognitive Abilities
SEP 05, 2020
Moderate Cannabis Use in Teenagers Reduces Cognitive Abilities
From studying adolescent siblings, researchers from the University of Colorado School of Medicine have found that modera ...
OCT 12, 2020
Cannabis Sciences
Can Cannabis Relieve Symptoms of Down Syndrome?
OCT 12, 2020
Can Cannabis Relieve Symptoms of Down Syndrome?
Increasing anecdotal and academic evidence has been emerging in recent years about the plethora of health benefits behin ...
OCT 14, 2020
Cannabis Sciences
Cannabis Users Remain Coy in Presence of Family
OCT 14, 2020
Cannabis Users Remain Coy in Presence of Family
A Canadian survey has found that 36 percent of cannabis users would consume cannabis during the holidays or other specia ...
Loading Comments...